Home Uncategorized FDA approves first anticoagulant for VTE in pediatric patients

FDA approves first anticoagulant for VTE in pediatric patients

Author(s):

On May 16, the FDA approved Fragmin (dalteparin sodium) injection to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients 1 month of age and older.

 

Read more at fda.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here